Compare Atmos Energy Corporation (ATO) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atmos Energy Corporation vs Merck & Co., Inc. — how do they compare? Atmos Energy Corporation trades at $174.98 (market cap $29.79B), while Merck & Co., Inc. trades at $123.93 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 10× Atmos Energy Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| ATO | MRK | |
|---|---|---|
Market Cap | $29.79B | $298.31B |
Sector | Utilities | Health |
52-Week High | $192.25 | $129.52 |
52-Week Low | $154.68 | $77.60 |
Enterprise Value | $39.29B | $341.72B |
Dividend Yield | 2.24% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $179.50, up 1.87% on the day, with a bullish technical outlook and strong support near $179. The stock shows solid fundamentals with a P/E of 22.11, revenue of $4.70B in 2025, and net income margin of 27.58%. Recent news highlights its position to benefit from data center demand and regulatory support, with an upcoming Q3 earnings call on August 6, 2026.
The outlook is positive with a consensus price target of $191.00, though risks include high capital expenditures and debt levels. Earnings growth and dividend stability provide upside, but investors should monitor execution on capex plans and interest rate impacts.
Merck (MRK) trades at $120.80, down 2.6% in the last session. The stock shows strong fundamentals with 2025 revenue of $65.01 billion and net income of $18.25 billion, yielding a net margin of 28.07%. Recent earnings beats and a bullish technical signal, with support at $120, highlight resilience. The acquisition of Terns Pharmaceuticals, announced April 7, 2026, aims to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive landscape.
The outlook for MRK is positive, supported by robust profitability, strategic acquisitions, and a consensus price target of $137.30. Risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and potential margin pressure from R&D investments. Institutional buying activity and a 67.57% buy rating from analysts underscore confidence, but investors should monitor execution risks and macroeconomic factors affecting the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
